Vivani Medical Stock News

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharm...

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. Vivani's Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “We made significant progress advancing ...